<DOC>
	<DOCNO>NCT00336817</DOCNO>
	<brief_summary>The objective study compare safety efficacy Myfortic CellCept liver transplant patient . Myfortic CellCept immunosuppressive ( anti-rejection ) drug . CellCept commonly use liver transplantation gastrointestinal ( GI ) side effect common , sometimes necessitating discontinuation . Myfortic new drug similar CellCept , except enteric-coated . Our hypothesis Myfortic le GI side effect CellCept also comparable effectiveness CellCept .</brief_summary>
	<brief_title>A Prospective Study Tolerability Efficacy de Novo Use Myfortic Liver Transplant Recipients</brief_title>
	<detailed_description>This prospective , randomize , double-blinded , single center , safety efficacy study compare Myfortic CellCept use liver transplantation . Patients biopsy-proven acute cellular rejection , renal insufficiency ( i.e . acute chronic renal failure require hemodialysis patient creatinine clearance &lt; 50 ml/min ) , calcineurin inhibitor-induced neurotoxicity ( define presence neurologic symptom tremor , alter mental status , seizure , etc ) randomize start either Myfortic ( 720 mg po bid ) CellCept ( 1 gm po bid ) . In patient calcineurin-induced neurotoxicity nephrotoxicity , tacrolimus cyclosporine dos also reduce maintain serum trough level 4-8 mg/dl 100-200 mg/dl , respectively . Comparison : Thirty patient enrol randomized two-armed , double-blinded studyâ€” half patient receive Myfortic half , CellCept .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>ALL patient adult liver transplant recipient , male female , 1880 year age . Patients must 30 180 day ( 1 6 month ) posttransplant eligible . Patients currently receive tacrolimus cyclosporine without corticosteroid part immunosuppressive regimen . Patients renal insufficiency ( history renal insufficiency renal failure past , patient hemodialysis , patient rise creatinine posttransplant ) . Patients biopsyproven acute cellular rejection ( mild , moderate , severe base Rejection Activity Index ( RAI ) grade pathologist UPMC ) repeat bouts rejection ( great 2 episode within 30 day period ) . Patients tacrolimus cyclosporineinduced neurotoxicity . Females childbearing potential must negative serum pregnancy test prior inclusion period . Multiorgan transplant patient . HIV positive patient . Livingrelated liver transplant recipient Pregnant patient nurse mother . Patients history extrahepatic malignancy within last five year , except excise squamous basal cell carcinoma skin . Patients thrombocytopenia ( &lt; 50,000/mm3 ) , absolute neutrophil count &lt; 1,000/mm3 and/or leukocytopenia ( &lt; 2,000/mm3 ) , and/or hemoglobin &lt; 7.0 g/dL prior enrollment . Presence clinically significant infection require continued therapy , severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus . Evidence drug and/or alcohol abuse . Decisionally impaired subject medically mentally capable provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>adverse effect</keyword>
</DOC>